CD274 and hepatocellular carcinoma: However, in the Phase III clinical trial IMbrave150, the combination of anti-PD-L1 and anti-vascular endothelial growth factor receptor (VEGFR) agents, atezolizumab plus bevacizumab (Atez/Bev), demonstrated significant OS improvement compared to sorafenib, becoming a recommended first-line treatment for advanced HCC (13).